In the longest clinical trial to date for HD chorea (open-label extension, non-blinded)1,2
For a progressive condition, 3 years of continued chorea control1,3
ARC-HD Study: TMC Score Reduction Maintained Through 3 Years4

Patients in the ARC-HD study received the AUSTEDO BID formulation.1
Sustained concentration over 24 hours4,5
- Bioequivalence of once-daily AUSTEDO XR has been established in pharmacokinetic profile studies4†
- Peak plasma concentrations (Cmax) of AUSTEDO® XR (deutetrabenazine) extended-release tablets are reached within approximately 3 hours5
Plasma Concentration at Steady State Over 24 Hours: AUSTEDO XR vs BID4‡

†Data supports bioequivalence of XR and BID across the full dosing range of AUSTEDO.1,5
‡Based on active alpha and beta metabolites.4
*ARC-HD was divided into 2 study cohorts: patients who rolled over from the pivotal trial and patients who switched overnight from tetrabenazine.5
ARC-HD was an open-label, single-arm, 2-cohort, 3-year extension study of the use of AUSTEDO in patients with HD chorea. The Rollover cohort had successfully completed FIRST-HD and underwent a 1-week washout prior to initiating 6 mg of AUSTEDO® (deutetrabenazine) tablets daily. The Switch cohort comprised patients with HD chorea who had been on a stable dose of tetrabenazine and were converted overnight to a dose of AUSTEDO predicted to provide comparable systemic exposure. A total of 119 patients with HD chorea were enrolled (Rollover cohort, n=82; Switch cohort, n=37). In both cohorts, dosage was titrated by 6 mg/day per week. Endpoints were changes in the UHDRS TMS and TMC scores from baseline to Week 8, as well as those from Week 8 to Week 145 (or end of treatment).1

Watch: Dr. Fahd Amjad discuss long-term results through 3 years
For more videos, visit the YouTube page.
HD, Huntington’s disease.
REFERENCES: 1. Frank S, Testa CM, Edmondson MC, et al. The safety of deutetrabenazine for chorea in Huntington Disease: an open-label extension study. CNS Drugs. 2022;36(11):1207-1216. doi:10.1007/s40263-022-00956-8 2. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology. 1988;38:391-394. 3. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997;48:358-362. 4. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. 5. AUSTEDO® XR (deutetrabenazine) extended-release tablets and AUSTEDO® current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc.